Immortal True Dragon sets up a $40 million longevity fund, focusing on investments in cutting-edge life extension technologies.
The mission-driven fund "Immortal True Dragon", headquartered in Singapore, recently announced that it will promote the development of radical life extension technologies with a unique investment philosophy. Currently, the fund manages assets worth $40 million and is committed to driving breakthroughs in longevity science and healthy lifespan research through the power of capital.
In the view of Immortal True Dragon, aging and death are technological challenges that can be overcome through scientific innovation. This concept permeates all its investment decisions, enabling it to prioritize social impact over mere financial returns when making investment plans.
Four Strategic Directions for Frontier Technology Deployment
To date, Immortal True Dragon has invested in over 20 industry-leading startups, with a focus on four strategic areas:
Firstly, replacement and regeneration technologies, including pioneering research such as xenotransplantation, cryopreservation, and biological tissue replacement or regeneration; secondly, gene therapy and delivery methods, targeting the root causes of aging and related diseases through gene therapy; thirdly, neural and brain aging reversal technologies, covering cutting-edge research such as neuronal regeneration, intervention in neurodegenerative diseases, and cognitive function enhancement, aiming to fundamentally delay and even reverse the brain aging process; fourthly, regulatory arbitrage and compliance paths, accelerating the transformation and implementation of innovative therapies by leveraging policy differences among different jurisdictions in the approval and clinical access of anti-aging therapies.
Boyang, the founder of the fund, said, "Whether it's cutting-edge scientific research or creating a better environment for scientific research, we are committed to finding investment opportunities that can bring about real impact." He also emphasized that the fund not only focuses on radical frontier technologies but also on the infrastructure construction that supports the implementation of these technologies, such as special economic zones.
Mission-Driven, Impact First
The first-phase fund of Immortal True Dragon is mainly funded by the founding team's own capital, with only one external limited partner, allowing it to quickly and decisively invest capital in the most promising projects. This model also enables it to support key projects that are overlooked by mainstream capital but have long-term value.
"We are a mission-driven fund, which means Immortal True Dragon values impact more than economic returns," Boyang said in a recent interview. "I invest in the longevity field because I hope to see real breakthroughs in this field."
It's worth mentioning that Boyang himself is one of the world's first 300 individuals to receive the Minicircle follistatin gene therapy, which also demonstrates the fund's determination to embrace frontier science. "The gene therapy was a personal experiment, but it does reflect our risk appetite and support for the longevity cause," he explained. "We have a strong motivation to support the first batch of longevity companies to achieve profitability, thereby promoting broader investment progress."
Actively Promoting Global Longevity Technology Development
In addition to capital deployment, Immortal True Dragon is also actively cultivating an ecosystem for global longevity technology development. The fund continuously invests in education promotion and community building, including translating scientific lectures and books in the longevity field, hosting and creating original Chinese longevity podcast content, funding scientific research projects at top anti-aging medical schools such as Stanford University and the University of Copenhagen, and supporting international anti-aging summits and organizations such as Vitalist Bay, ARDD 2025, and the Alzheimer's Association in the United States. In the view of Immortal True Dragon, the progress of the longevity industry not only requires capital investment but also depends on the awakening of public awareness and the improvement of infrastructure.
Professor Peter Lidsky from the Department of Biomedical Sciences at City University of Hong Kong recalled, "Meeting the Immortal True Dragon team at the Vitalist Bay conference in Berkeley earlier this year was very inspiring. These young, brave, and energetic people are committed to solving a major challenge faced by humanity - aging. They provided great help in translating my lecture into Chinese, and I look forward to deeper cooperation in the future."
Aubrey de Grey, the chairman of the LEV Foundation, also said, "It's a pleasure to know the Immortal True Dragon team. For years, I've been regretting the lack of attention in the Chinese longevity field. Now, the situation is changing. This team is introducing the work of me and other researchers to the Chinese public, and I'm very glad to see them investing in promising longevity startups."
As a practitioner of mission-driven investment, Immortal True Dragon is breaking the status quo, providing a new perspective on human healthy lifespan, expanding the boundaries of science, and carrying forward the torch of the life extension cause.